nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe
![Nurix Therapeutics logo](/files/LOGO/1549595-NRIX.png)
Company profile
Ticker
NRIX
Exchange
Website
CEO
Arthur T. Sands
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Nurix, Inc.
SEC CIK
Corporate docs
Subsidiaries
DeCART Therapeutics Inc. ...
IRS number
270838048
NRIX stock data
Latest filings (excl ownership)
424B5
Prospectus supplement for primary offering
11 Jul 24
10-Q
2024 Q2
Quarterly report
11 Jul 24
8-K
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
11 Jul 24
8-K
Regulation FD Disclosure
17 Jun 24
S-3ASR
Automatic shelf registration
11 Jun 24
8-K
Submission of Matters to a Vote of Security Holders
21 May 24
8-K
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
12 Apr 24
424B5
Prospectus supplement for primary offering
12 Apr 24
424B5
Prospectus supplement for primary offering
11 Apr 24
10-Q
2024 Q1
Quarterly report
10 Apr 24
Latest ownership filings
4
Lori Anne Kunkel
18 Jul 24
4
Christine Ring
1 Jul 24
144
Notice of proposed sale of securities
1 Jul 24
4
Houte Hans van
20 Jun 24
144
Notice of proposed sale of securities
20 Jun 24
4
Christine Ring
13 Jun 24
4
Christine Ring
12 Jun 24
SC 13G/A
BlackRock Inc.
7 Jun 24
4
Christine Ring
5 Jun 24
4
Christine Ring
3 Jun 24
Financial summary
Quarter (USD) | May 24 | Feb 24 | Nov 23 | Aug 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Nov 23 | Nov 22 | Nov 21 | Nov 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 117.69 mm | 117.69 mm | 117.69 mm | 117.69 mm | 117.69 mm | 117.69 mm |
Cash burn (monthly) | (no burn) | (no burn) | 16.18 mm | 14.93 mm | 13.24 mm | 8.01 mm |
Cash used (since last report) | n/a | n/a | 30.19 mm | 27.85 mm | 24.70 mm | 14.94 mm |
Cash remaining | n/a | n/a | 87.50 mm | 89.84 mm | 93.00 mm | 102.75 mm |
Runway (months of cash) | n/a | n/a | 5.4 | 6.0 | 7.0 | 12.8 |
Institutional ownership, Q1 2024
76.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 131 |
Opened positions | 57 |
Closed positions | 17 |
Increased positions | 27 |
Reduced positions | 30 |
13F shares | Current |
---|---|
Total value | 652.44 bn |
Total shares | 49.31 mm |
Total puts | 22.70 k |
Total calls | 30.30 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 4.58 mm | $67.33 bn |
Redmile | 4.48 mm | $65.90 bn |
Baker Bros. Advisors | 3.88 mm | $57.07 bn |
Deep Track Capital | 3.00 mm | $44.07 bn |
STT State Street | 2.73 mm | $40.12 bn |
ARK Investment Management | 2.64 mm | $38.74 bn |
Vanguard | 2.58 mm | $37.99 bn |
MS Morgan Stanley | 2.53 mm | $37.20 bn |
T. Rowe Price | 2.20 mm | $32.28 mm |
Deutsche Bank AG - Registered Shares | 1.50 mm | $22.04 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Jul 24 | Lori Anne Kunkel | Common Stock | Gift | Dispose G | No | No | 0 | 54,027 | 0.00 | 0 |
1 Jul 24 | Christine Ring | Common Stock | Sell | Dispose S | No | Yes | 21.5697 | 801 | 17.28 k | 19,838 |
1 Jul 24 | Christine Ring | Common Stock | Sell | Dispose S | No | Yes | 20.6815 | 4,959 | 102.56 k | 20,639 |
1 Jul 24 | Christine Ring | Common Stock | Option exercise | Acquire M | No | Yes | 1.86 | 5,760 | 10.71 k | 25,598 |
1 Jul 24 | Christine Ring | Employee Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 1.86 | 5,760 | 10.71 k | 88,546 |
20 Jun 24 | Houte Hans van | Common Stock | Sell | Dispose S | No | Yes | 20.0108 | 20,000 | 400.22 k | 48,333 |
13 Jun 24 | Christine Ring | Common Stock | Sell | Dispose S | No | Yes | 17.0178 | 1,864 | 31.72 k | 19,838 |
13 Jun 24 | Christine Ring | Common Stock | Option exercise | Acquire M | No | Yes | 1.86 | 1,864 | 3.47 k | 21,702 |
13 Jun 24 | Christine Ring | Employee Stock Option Common Stock | Option exercise | Dispose M | No | Yes | 1.86 | 1,864 | 3.47 k | 94,306 |
12 Jun 24 | Christine Ring | Common Stock | Sell | Dispose S | No | Yes | 17.01 | 1,900 | 32.32 k | 19,838 |
News
Analyst Scoreboard: 12 Ratings For Nurix Therapeutics
15 Jul 24
JP Morgan Maintains Overweight on Nurix Therapeutics, Raises Price Target to $34
15 Jul 24
Barclays Maintains Overweight on Nurix Therapeutics, Raises Price Target to $31
15 Jul 24
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $27
12 Jul 24
Needham Maintains Buy on Nurix Therapeutics, Lowers Price Target to $29
12 Jul 24
Press releases
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
11 Jul 24
Nurix Therapeutics to Participate in the UBS Virtual Targeted Protein Degradation (TPD) Day
8 Jul 24
Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)
16 Jun 24
Nurix Therapeutics to Host a Webcast and Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of NX-5948 Being Presented at the European Hematology Association Congress (EHA2024)
10 Jun 24
Nurix Therapeutics Appoints Paula G. O'Connor, M.D., as Chief Medical Officer and Pasit Phiasivongsa, Ph.D., as Chief Technical Officer
28 May 24